Emergent BioSolutions (NYSE: EBS) director sells shares and receives RSUs, options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Emergent BioSolutions director Keith Katkin reported both a sale and new equity awards. He sold 15,481 shares of common stock at a weighted average price of $8.28 per share under a Rule 10b5-1 trading plan to satisfy tax obligations from RSUs that vested on April 29, 2026. On the same date, he received an annual grant of 25,344 restricted stock units for board and committee service, which will vest the day before the one-year anniversary of the grant if he remains on the board. He also received 11,296 stock options with a $7.99 exercise price, expiring April 30, 2033, and reported holding 111,775 shares directly after these transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 15,481 shares ($128,183)
Net Sell
3 txns
Insider
Katkin Keith
Role
null
Sold
15,481 shs ($128K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (Right to Buy) | 11,296 | $0.00 | -- |
| Grant/Award | Common Stock | 25,344 | $0.00 | -- |
| Sale | Common Stock | 15,481 | $8.28 | $128K |
Holdings After Transaction:
Stock Options (Right to Buy) — 11,296 shares (Direct, null);
Common Stock — 111,775 shares (Direct, null)
Footnotes (1)
- Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 10, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026. The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.23 to $8.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Key Figures
Shares sold: 15,481 shares
Sale price: $8.28 per share
RSU grant: 25,344 shares
+4 more
7 metrics
Shares sold
15,481 shares
Open-market sale on April 30, 2026
Sale price
$8.28 per share
Weighted average sale price
RSU grant
25,344 shares
Annual restricted stock unit award for director service
Option grant size
11,296 options
Stock options granted for board and committee service
Option exercise price
$7.99 per share
Exercise price for new stock options
Option expiration
April 30, 2033
Expiration date of granted stock options
Shares held after transactions
111,775 shares
Direct common stock holdings after reported Form 4
Key Terms
restricted stock units ("RSUs"), Rule 10b5-1 trading plan, Stock Options (Right to Buy), Black-Scholes value
4 terms
restricted stock units ("RSUs") financial
"Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive Plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Rule 10b5-1 trading plan regulatory
"Shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 10, 2025"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Options (Right to Buy) financial
"security_title": "Stock Options (Right to Buy)""
Black-Scholes value financial
"dividing by the Black-Scholes value of a single option calculated as of the date of the grant"
FAQ
What insider transactions did Emergent BioSolutions (EBS) director Keith Katkin report?
Katkin reported selling 15,481 Emergent BioSolutions shares and receiving new equity awards. The sale was an open‑market transaction, while he also received 25,344 restricted stock units and 11,296 stock options as part of his annual non‑employee director compensation package.
What new equity awards did Keith Katkin receive from Emergent BioSolutions (EBS)?
Katkin received 25,344 restricted stock units and 11,296 stock options for board and committee service. Each RSU converts into one common share at vesting, and each option allows purchase of one share at the fixed exercise price specified in the grant.
When do Keith Katkin’s new Emergent BioSolutions (EBS) RSUs and options vest?
Both the RSUs and stock options vest on the day before the one‑year anniversary of the grant date. Vesting is conditioned on Katkin continuing to serve on Emergent BioSolutions’ board of directors through that vesting date, according to the filing.